Witek M, Larkey N, Bartakova A, Hupert M, Mog S, Cronin J
Int J Mol Sci. 2024; 25(19.
PMID: 39408948
PMC: 11477226.
DOI: 10.3390/ijms251910619.
Tang S, Zhang Q
World J Clin Cases. 2023; 11(25):6000-6004.
PMID: 37727473
PMC: 10506021.
DOI: 10.12998/wjcc.v11.i25.6000.
Shim J, Park S, Venkateswaran S, Kumar D, Prince C, Parihar V
Blood. 2023; 142(23):1972-1984.
PMID: 37624902
PMC: 10731577.
DOI: 10.1182/blood.2023020426.
Sugisaki M, Imamura K, Terasaki Y, Iino H, Hoshino T, Hatsumi N
SAGE Open Med Case Rep. 2023; 11:2050313X231177758.
PMID: 37284224
PMC: 10240553.
DOI: 10.1177/2050313X231177758.
Tariq H, Zahra U
Turk J Haematol. 2021; 39(1):80-81.
PMID: 34792307
PMC: 8886273.
DOI: 10.4274/tjh.galenos.2021.2021.0480.
Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma.
Wang W, Li Y, Rivera Rivera X, Zhao L, Mei D, Hu W
BMC Cancer. 2021; 21(1):1011.
PMID: 34503477
PMC: 8431857.
DOI: 10.1186/s12885-021-08753-0.
Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
Liu Z, Li Y, Shi C
Int J Hematol. 2021; 113(3):337-343.
PMID: 33502735
DOI: 10.1007/s12185-021-03085-y.
Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease.
Tavarozzi R, Manzato E, Morganti R, Sammuri P, Tarrini G, Ricci F
Leuk Res Rep. 2021; 15:100234.
PMID: 33489749
PMC: 7810761.
DOI: 10.1016/j.lrr.2021.100234.
The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease.
Liao H, Zheng Q, Jin Y, Chozom T, Zhu Y, Liu L
Sci Rep. 2019; 9(1):19722.
PMID: 31871314
PMC: 6928064.
DOI: 10.1038/s41598-019-56126-2.
Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
Wenzinger C, Williams E, Gru A
Curr Hematol Malig Rep. 2018; 13(4):275-288.
PMID: 29951888
DOI: 10.1007/s11899-018-0456-8.
[Prognostic value of bone marrow hematogones in childhood B-lineage acute lymphoblastic leukemia].
Wang Y, Jiang Y, Gao J, Zhou P, Zhang G
Zhongguo Dang Dai Er Ke Za Zhi. 2016; 18(4):292-6.
PMID: 27097570
PMC: 7390085.
Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I, Hirota S
Int J Clin Exp Pathol. 2015; 8(8):9737-41.
PMID: 26464748
PMC: 4583980.
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study.
Carulli G, Ottaviano V, Sammuri P, Domenichini C, Guerri V, Rousseau M
Int J Hematol. 2015; 102(1):59-66.
PMID: 25953308
DOI: 10.1007/s12185-015-1798-9.
Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
Reis-Alves S, Traina F, Metze K, Lorand-Metze I
Diagn Pathol. 2015; 10:44.
PMID: 25924846
PMC: 4428240.
DOI: 10.1186/s13000-015-0259-3.
Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-lymphocyte clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas.
Carulli G, Ottaviano V, Guerri V, Giuntini S, Sammuri P, Ciancia E
Hematol Rep. 2014; 6(2):5381.
PMID: 25013717
PMC: 4091289.
DOI: 10.4081/hr.2014.5381.
